Regenicin, Inc.

OTCPK:RGIN Stock Report

Market Cap: US$15.3k

Regenicin Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Randy McCoy

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure14.5yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure14.3yrs

Recent management updates

No updates

Recent updates

CEO Compensation Analysis

How has Randy McCoy's remuneration changed compared to Regenicin's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2023n/an/a

-US$985k

Dec 31 2022n/an/a

-US$816k

Sep 30 2022US$250kUS$250k

-US$692k

Jun 30 2022n/an/a

-US$666k

Mar 31 2022n/an/a

-US$669k

Dec 31 2021n/an/a

-US$735k

Sep 30 2021US$250kUS$250k

-US$741k

Jun 30 2021n/an/a

-US$630k

Mar 31 2021n/an/a

-US$637k

Dec 31 2020n/an/a

-US$592k

Sep 30 2020US$250kUS$250k

-US$631k

Jun 30 2020n/an/a

-US$779k

Mar 31 2020n/an/a

-US$790k

Dec 31 2019n/an/a

-US$780k

Sep 30 2019US$250kUS$250k

-US$829k

Jun 30 2019n/an/a

-US$611k

Mar 31 2019n/an/a

-US$614k

Dec 31 2018n/an/a

-US$669k

Sep 30 2018US$250kUS$250k

-US$630k

Compensation vs Market: Insufficient data to establish whether Randy's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare Randy's compensation with company performance.

CEO

Randy McCoy (75 yo)

14.5yrs

Tenure

US$250,000

Compensation

Mr. Randall E. McCoy, also known as Randy, has been Chief Executive Officer and Chairman of the Board of Regenicin, Inc. since July 2010 and serves as its President. He founded McCoy Enterprises LLC in May...

Board Members

NamePositionTenureCompensationOwnership
Randall McCoy
Chairman14.5yrsUS$250.00kno data
John Weber
CFO & Director14.3yrsUS$125.00kno data
Gervaise Gerstner
Member of Scientific Advisory Board14.3yrsno datano data

14.3yrs

Average Tenure

Experienced Board: RGIN's board of directors are seasoned and experienced ( 14.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/12 13:43
End of Day Share Price 2024/12/30 00:00
Earnings2023/03/31
Annual Earnings2022/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Regenicin, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution